A61K31/546

LIPOSOMAL TROPONOID COMPOUND FORMULATIONS
20220339136 · 2022-10-27 ·

The present disclosure is concerned with liposomal formulations comprising troponoid compounds and methods of using same in the treatment of, for example, viral infections, antimicrobial infections, cancer, inflammatory diseases, and cardiovascular diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

LIPOSOMAL TROPONOID COMPOUND FORMULATIONS
20220339136 · 2022-10-27 ·

The present disclosure is concerned with liposomal formulations comprising troponoid compounds and methods of using same in the treatment of, for example, viral infections, antimicrobial infections, cancer, inflammatory diseases, and cardiovascular diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

LIPOSOMAL TROPONOID COMPOUND FORMULATIONS
20220339136 · 2022-10-27 ·

The present disclosure is concerned with liposomal formulations comprising troponoid compounds and methods of using same in the treatment of, for example, viral infections, antimicrobial infections, cancer, inflammatory diseases, and cardiovascular diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Beta-lactamases with improved properties for therapy

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

Beta-lactamases with improved properties for therapy

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

Beta-lactamases with improved properties for therapy

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

EXOGENOUS NITRIC OXIDE FOR IMPROVED SUSCEPTIBILITY AND LOWERED ANTIBIOTIC RESISTANCE IN RESISTANT RESPIRATORY BACTERIA
20230082968 · 2023-03-16 ·

Disclosed are antimicrobial compositions and formulations directed against a broad range of bacteria and Pseudomonas aeruginosa biofilms. In an aspect, the compositions and formulations do not engender resistance. In an aspect, in combination with antibiotics, the compositions and formulations slow the development of antibiotic-resistance and greatly improve bacterial susceptibility to multiple classes of antibiotics.

EXOGENOUS NITRIC OXIDE FOR IMPROVED SUSCEPTIBILITY AND LOWERED ANTIBIOTIC RESISTANCE IN RESISTANT RESPIRATORY BACTERIA
20230082968 · 2023-03-16 ·

Disclosed are antimicrobial compositions and formulations directed against a broad range of bacteria and Pseudomonas aeruginosa biofilms. In an aspect, the compositions and formulations do not engender resistance. In an aspect, in combination with antibiotics, the compositions and formulations slow the development of antibiotic-resistance and greatly improve bacterial susceptibility to multiple classes of antibiotics.

Methods to control infection using new generation small molecule growth inhibitors

Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants.

Methods to control infection using new generation small molecule growth inhibitors

Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants.